Evidence map›Paper›PMID 26199856›Full record

ArticleAnalytical cellular pathology (Amsterdam)2015

Epstein-Barr virus association with peptic ulcer disease.

María G Cárdenas-Mondragón, Javier Torres, Lourdes Flores-Luna, Ricardo Carreón-Talavera, Margarita Camorlinga-Ponce, Ezequiel M Fuentes-Pananá

Open access · goldAbstract read
In one paragraph

Article in Analytical cellular pathology (Amsterdam), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Evaluation ofAnnals of medicine and surgery (2012) · 2023
    Article
  3. Article
  4. Epstein-Barr Virus Infection Is Associated with Elevated Hepcidin Levels.International journal of molecular sciences · 2023
    Article
  5. Review
  6. Network Pharmacology and Molecular Docking Analysis on Pharmacological Mechanisms ofEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  7. Article
  8. Gastroprotective activity and pharmacological safety evaluation ofExperimental and therapeutic medicine · 2019
    Article
  9. Gastroduodenal Injury: Role of Protective Factors.Current gastroenterology reports · 2019
    Review
  10. Article
  11. Gut pathogens · 2017
    Article
  12. Elevated Levels of Interferon-Journal of immunology research · 2017
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

María G Cárdenas-MondragónUnidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias (UIMEIP), Hospital de Pediatría, CMN Siglo-XXI, Instituto Mexicano del Seguro Social (IMSS), Avenida Cuauhtémoc 330, Colonia Doctores, Delegación Cuauhtémoc, 06720 Ciudad de México, DF, Mexico.
Javier TorresUnidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias (UIMEIP), Hospital de Pediatría, CMN Siglo-XXI, Instituto Mexicano del Seguro Social (IMSS), Avenida Cuauhtémoc 330, Colonia Doctores, Delegación Cuauhtémoc, 06720 Ciudad de México, DF, Mexico.
Lourdes Flores-LunaCentro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Avenida Universidad 655, Colonia Santa María Ahuacatitlán, 62100 Cuernavaca, MOR, Mexico.
Ricardo Carreón-TalaveraUnidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias (UIMEIP), Hospital de Pediatría, CMN Siglo-XXI, Instituto Mexicano del Seguro Social (IMSS), Avenida Cuauhtémoc 330, Colonia Doctores, Delegación Cuauhtémoc, 06720 Ciudad de México, DF, Mexico.
Margarita Camorlinga-PonceUnidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias (UIMEIP), Hospital de Pediatría, CMN Siglo-XXI, Instituto Mexicano del Seguro Social (IMSS), Avenida Cuauhtémoc 330, Colonia Doctores, Delegación Cuauhtémoc, 06720 Ciudad de México, DF, Mexico.
Ezequiel M Fuentes-PananáUnidad de Investigación en Virología y Cáncer, Hospital Infantil de México Federico Gómez, Dr. Márquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Ciudad de México, DF, Mexico.
Mexican Social Security Institute · MXHospital Infantil de México Federico Gómez · MXInstituto Nacional de Salud Pública · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background. Helicobacter pylori (HP) infection and nonsteroidal anti-inflammatory drugs (NSAID) use are considered the main risk to develop peptic ulcer disease (PUD). However, PUD also occurs in the absence of HP infection and/or NSAID use. Recently, we have found evidence that Epstein-Barr virus (EBV) reactivation increases the risk to develop premalignant and malignant gastric lesions. Objective. To study a possible association between EBV and PUD. Methods. Antibodies against an EBV reactivation antigen, HP, and the HP virulence factor CagA were measured in sera from 207 Mexican subjects, controls (healthy individuals, n = 129), and PUD patients (n = 78, 58 duodenal and 20 gastric ulcers). Statistical associations were estimated. Results. Duodenal PUD was significantly associated with high anti-EBV IgG titers (p = 0.022, OR = 2.5), while anti-EBV IgA was positively associated with gastric PUD (p = 0.002, OR = 10.1). Conclusions. Our study suggests that EBV reactivation in gastric and duodenal epithelium increases the risk to develop PUD.

Indexed as

AdultAntibodies, ViralDuodenal UlcerEpstein-Barr Virus InfectionsFemaleHelicobacter InfectionsHerpesvirus 4, HumanHumansImmunoglobulin GMaleMiddle AgedOdds RatioPeptic UlcerRisk FactorsStomach UlcerAntibodies, ViralImmunoglobulin G

Identifiers

PMID26199856
PMCPMC4495172
OpenAlexW1526304109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.